Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician

Rheumatoid arthritis (RA) is a disease characterised by inflammation of synovial joints and poses a substantial healthcare burden on both the individual and society. One of the most significant shifts in the RA therapeutic landscape has occurred with the introduction of biological disease modifying...

Descripción completa

Detalles Bibliográficos
Autores principales: Findeisen, Kate E, Sewell, Julia, Ostor, Andrew J K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370108/
https://www.ncbi.nlm.nih.gov/pubmed/34413630
http://dx.doi.org/10.2147/BTT.S252575
_version_ 1783739411928711168
author Findeisen, Kate E
Sewell, Julia
Ostor, Andrew J K
author_facet Findeisen, Kate E
Sewell, Julia
Ostor, Andrew J K
author_sort Findeisen, Kate E
collection PubMed
description Rheumatoid arthritis (RA) is a disease characterised by inflammation of synovial joints and poses a substantial healthcare burden on both the individual and society. One of the most significant shifts in the RA therapeutic landscape has occurred with the introduction of biological disease modifying anti-rheumatic drugs (bDMARDs). There are five classes of bDMARDs currently available, each with a different molecular target and subtle differences in their efficacy and safety profile. This review also describes the “real-world” use of bDMARDs and how they fit into the overall RA treatment guidelines.
format Online
Article
Text
id pubmed-8370108
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-83701082021-08-18 Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician Findeisen, Kate E Sewell, Julia Ostor, Andrew J K Biologics Review Rheumatoid arthritis (RA) is a disease characterised by inflammation of synovial joints and poses a substantial healthcare burden on both the individual and society. One of the most significant shifts in the RA therapeutic landscape has occurred with the introduction of biological disease modifying anti-rheumatic drugs (bDMARDs). There are five classes of bDMARDs currently available, each with a different molecular target and subtle differences in their efficacy and safety profile. This review also describes the “real-world” use of bDMARDs and how they fit into the overall RA treatment guidelines. Dove 2021-08-12 /pmc/articles/PMC8370108/ /pubmed/34413630 http://dx.doi.org/10.2147/BTT.S252575 Text en © 2021 Findeisen et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Findeisen, Kate E
Sewell, Julia
Ostor, Andrew J K
Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician
title Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician
title_full Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician
title_fullStr Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician
title_full_unstemmed Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician
title_short Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician
title_sort biological therapies for rheumatoid arthritis: an overview for the clinician
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370108/
https://www.ncbi.nlm.nih.gov/pubmed/34413630
http://dx.doi.org/10.2147/BTT.S252575
work_keys_str_mv AT findeisenkatee biologicaltherapiesforrheumatoidarthritisanoverviewfortheclinician
AT sewelljulia biologicaltherapiesforrheumatoidarthritisanoverviewfortheclinician
AT ostorandrewjk biologicaltherapiesforrheumatoidarthritisanoverviewfortheclinician

Ejemplares similares